跳转至内容
Merck
CN

F6127

醋酸氟可的松

synthetic, ≥98%, glucocorticoid activity, powder

别名:

9α-Fluoro-11β,17α,21-trihydroxy-4-pregnene-3,20-dione acetate, 9-Fluorocortisol acetate, 9-Fluorohydrocortisone acetate

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C23H31FO6
化学文摘社编号:
分子量:
422.49
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
208-180-4
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

醋酸氟可的松, ≥98%

InChI key

SYWHXTATXSMDSB-GSLJADNHSA-N

InChI

1S/C23H31FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h10,16-18,27,29H,4-9,11-12H2,1-3H3/t16-,17-,18-,20-,21-,22-,23-/m0/s1

SMILES string

CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C

biological source

synthetic

sterility

non-sterile

assay

≥98%

form

powder

solubility

acetone: 50 mg/mL, clear, colorless to light yellow

shipped in

ambient

storage temp.

room temp

Quality Level

Gene Information

human ... NR3C2(4306)

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

Fludrocortisone acetate is a synthetic corticosteroid with more mineralocorticoid than glucocorticoid activity.

General description

Fludrocortisone acetate is secreted by adrenal cortex. It increases the reabsorption of sodium and secretion of potassium and hydrogen. Fludrocortisone is used to treat cerebral salt wasting syndrome and adrenal insufficiency. Fludrocortisone improves the sensitivity of blood vessels to catecholamines and increases the blood volume.

pictograms

Health hazardExclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
Annane D, et al.
JAMA : The Journal of the American Medical Association, 288(7), 862-871 (2002)
S Yamashiro et al.
Acta neurochirurgica, 139(10), 987-990 (1997-01-01)
This 67 year-old man experienced 3 episodes of symptomatic hyponatraemia. Radiological examination revealed a sellar lesion and the tumour was removed via the transsphenoidal route. Thereafter, he simultaneously developed intractable diabetes insipidus and serious hyponatraemia with persistent natriuresis. His level
R Taniguchi et al.
The Tohoku journal of experimental medicine, 186(3), 215-223 (1999-05-29)
It is known that some patients with primary aldosteronism show postoperative hyperkalemia, which is due to inability of the adrenal gland to secrete sufficient amounts of aldosterone. However, hyperkalemia is generally neither severe nor prolonged, in which replacement therapy with
Clinical Pharmacology Made Incredibly Easy! (2009)
Dong-Min Kim et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 22(11), 3273-3276 (2007-07-10)
Hyperkalaemia is a commonly encountered problem in dialysis patients with end-stage renal disease (ESRD). The aim of the present study was to assess the effect of fludrocortisone acetate (FCA) on reducing serum potassium levels in haemodialysis (HD) patients with hyperkalaemia.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持